Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-12.98 Insider Own3.49% Shs Outstand2.31M Perf Week-2.47%
Market Cap10.05M Forward P/E- EPS next Y-5.60 Insider Trans287.63% Shs Float2.23M Perf Month-10.31%
Income-26.82M PEG- EPS next Q-2.51 Inst Own11.18% Short Float0.95% Perf Quarter-45.86%
Sales0.00M P/S- EPS this Y45.92% Inst Trans4.87% Short Ratio0.52 Perf Half Y-43.14%
Book/sh9.34 P/B0.47 EPS next Y31.29% ROA-65.50% Short Interest0.02M Perf Year-53.60%
Cash/sh7.28 P/C0.60 EPS next 5Y- ROE-79.75% 52W Range4.20 - 15.75 Perf YTD-66.22%
Dividend Est.- P/FCF- EPS past 5Y18.25% ROI-121.72% 52W High-72.38% Beta1.87
Dividend TTM- Quick Ratio3.51 Sales past 5Y0.00% Gross Margin- 52W Low3.57% ATR (14)0.37
Dividend Ex-Date- Current Ratio3.51 EPS Y/Y TTM17.54% Oper. Margin0.00% RSI (14)41.04 Volatility6.78% 6.95%
Employees18 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price30.00
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q51.20% Payout- Rel Volume0.24 Prev Close4.32
Sales Surprise- EPS Surprise42.78% Sales Q/Q- EarningsMay 13 BMO Avg Volume40.78K Price4.35
SMA20-7.66% SMA50-8.76% SMA200-40.17% Trades Volume9,671 Change0.69%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $14
Jun-12-24 09:00AM
Jun-10-24 08:00AM
Jun-05-24 08:55AM
May-16-24 08:32AM
08:38AM Loading…
May-15-24 08:38AM
May-14-24 03:00AM
May-13-24 07:30AM
May-10-24 09:52PM
May-09-24 08:30AM
May-08-24 08:45AM
May-07-24 08:55AM
May-02-24 09:00AM
May-01-24 08:50AM
Apr-25-24 09:45AM
08:30AM Loading…
Apr-18-24 08:30AM
Apr-10-24 08:30AM
Mar-28-24 10:45AM
Mar-27-24 09:25AM
Mar-26-24 08:36AM
Mar-25-24 07:30AM
Mar-22-24 08:52PM
Mar-20-24 07:30AM
Mar-19-24 04:30PM
Mar-12-24 09:05AM
Jan-24-24 08:50AM
Dec-20-23 09:16PM
08:50AM Loading…
Dec-11-23 08:50AM
Nov-14-23 01:46PM
Nov-13-23 08:05AM
Nov-07-23 08:45AM
Nov-06-23 08:35AM
Oct-24-23 07:45AM
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Oct-02-23 08:40AM
Sep-22-23 07:58AM
Sep-21-23 08:50AM
Sep-18-23 08:40AM
Sep-14-23 08:35AM
Sep-05-23 08:35AM
Aug-12-23 12:16AM
Aug-11-23 06:45AM
Aug-10-23 04:05PM
Aug-07-23 08:40AM
Aug-03-23 08:45AM
Jul-13-23 08:40AM
Jul-06-23 08:45AM
Jun-13-23 08:35AM
May-30-23 09:05AM
May-12-23 11:15AM
May-11-23 08:04AM
May-10-23 04:05PM
May-04-23 08:35AM
May-02-23 08:35AM
Apr-24-23 09:55AM
Apr-18-23 05:33PM
Mar-27-23 12:00PM
Mar-24-23 05:33AM
Mar-23-23 07:10AM
Mar-22-23 04:20PM
Mar-21-23 08:50AM
Mar-15-23 08:30AM
Mar-13-23 08:35AM
Mar-09-23 08:35AM
Mar-01-23 08:45AM
Feb-13-23 11:30AM
Jan-11-23 01:00PM
Jan-05-23 08:45AM
Dec-21-22 08:25AM
Dec-19-22 09:15AM
Dec-15-22 01:09PM
Dec-07-22 08:45AM
Nov-14-22 05:23PM
Nov-10-22 04:05PM
Nov-07-22 09:05AM
Oct-14-22 08:40AM
Sep-27-22 01:01PM
Sep-23-22 09:11AM
Sep-08-22 08:45AM
Sep-07-22 08:35AM
Sep-06-22 08:45AM
Aug-19-22 08:40AM
Aug-15-22 08:35AM
Jul-28-22 08:35AM
Jul-11-22 10:22AM
Jul-08-22 08:35AM
Jun-16-22 08:35AM
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLEMP WALTER VCEO and PresidentDec 26 '23Buy0.69188,404129,999680,880Dec 27 07:31 AM
Foster Jonathan P.Chief Financial OfficerDec 26 '23Buy0.6928,98620,00080,556Dec 27 07:32 AM
George Robert E.DirectorDec 26 '23Buy0.6914,49310,00014,660Dec 27 07:31 AM